Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The BRAF gene mutation rate was 7.23% in peripheral blood of 23 patients with nonsmall-cell lung cancer, and was 5.45% in 14 cancer tissues, the mutation consistency was 80.00% in peripheral blood-tumor tissue matched samples.
|
25450274 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.
|
15046639 |
2004 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combined BRAF and EGFR inhibition blocked reactivation of ERK signaling and improved efficacy in vitro and in vivo Our findings support the evaluation of combined BRAF and EGFR inhibition in NSCLC(V600E) with acquired resistance to BRAF inhibitors.
|
27196768 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We highlight the conventional mechanisms of drug resistance elicited by the complex heterogeneous microenvironment of NSCLC during targeted therapy, including mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), the receptor tyrosine kinase ROS proto-oncogene 1 (ROS1), and the serine/threonine-protein kinase BRAF (v-Raf murine sarcoma viral oncogene homolog B).
|
31715289 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
MC1R variants increase risk of melanomas harboring BRAF mutations.
|
18368129 |
2008 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.
|
29164615 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
|
21190184 |
2011 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation.
|
29662327 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The sensitivity of NSCLC with kinase-impaired BRAF to dasatinib suggested synthetic lethality of BRAF and an unknown dasatinib target.
|
22649091 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
A structural systems biology approach for quantifying the systemic consequences of missense mutations in proteins.
|
23093928 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, the methods of molecular detection presently applied in clinical practice, particularly detection of BRAF in NSCLC patients, require further investigation.
|
29467863 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
|
22535154 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, in this review, we outline the preclinical and clinical data for BRAF and MEK inhibitor combination treatment for NSCLC patients with BRAF V600E mutation.
|
29595366 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
|
21343559 |
2011 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four (24%) of 17 BRAF-mutated melanoma had partial response as did four (20%) of 20 BRAF wild-type melanoma and two (11%) of 18 KRAS-mutant NSCLC.
|
24947927 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Trametinib in combination with the BRAF inhibitor dabrafenib represents the first MEK1/2 inhibitor containing regimen that is approved for advanced BRAF<sup>V600E</sup>-mutant NSCLC.
|
29216787 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We tested two different options to enhance the efficacy of vemurafenib (BRAF V600E inhibitor) in BRAF mutated NSCLC.
|
25706985 |
2015 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
|
31470866 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.
|
27283860 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To determine whether loss of wild-type KRAS is involved in the development of human lung cancer, we investigated the mutations of KRAS, NRAS and BRAF in 154 primary non-small cell lung cancers (NSCLCs) as well as 10 NSCLC cell lines that have been shown to have KRAS mutations.
|
14601056 |
2003 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Using this assay, we confirmed that BRAF mutations can be identified in a minority of NSCLC tumors and that patients whose tumors harbor BRAF mutations have a distinct clinical profile compared with those whose tumors harbor kinase domain mutations in EGFR.
|
19010912 |
2008 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the present study, the frequency and type of KRAS and BRAF mutation were assessed in 145 FFPE tissue samples from CNS metastases of NSCLC.
|
25902737 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR+ (del 19, L858R, G719X, S768I, L851Q) NSCLC clinical samples (formalin-fixed paraffin-embedded tumor and blood) were analyzed for the presence of receptor tyrosine kinase (RTK) and BRAF fusions.
|
29883838 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Missense mutations of the BRAF gene in human lung adenocarcinoma.
|
12460919 |
2002 |